Comment · Wed, February 12, 2014
MDA with a SSRI
Original post in this thread
wolpertinger777 · 12 points
I'm a huge fan of MDA for its psychedelic properties. It has a really special "outrospection" that I have yet to experience in other substances.
The only problem for me is its supposed neurotoxicity because of monoamine release. Would using an SSRI (such as kanna) remove the serotonin releasing properties of the drug and therefore curb the issue of neurotoxicity?
I know that the compound might feel a little different without the serotonin release and the psychedelia might require higher dosages but would it still be effective?
TO SUM UP: Would using an SSRI (such as kanna) with MDA block the serotonin releasing properties and thereby create a non-neurotoxic dopamine/norepinephrine releasing agent with 5ht2a agonism?
What they were answering
Herperderperton · 1 points
That paper that you linked would suggest that LSD is a 5-ht2b agonist as well, which was confirmed by another paper I found. 5-ht2b activation on cardiac valvular fibroblasts causes them to proliferate and is responsible for a pathological thickening observed in fenfluramine users and MDMA users. I have never heard about this occurring from DMT use (maybe because its 5-ht2b activation tends to be less prolonged due to its half life and used less frequently) or for LSD.
u/MisterYouAreSoDumb
I would assume that is due to the much smaller active dosages with DMT and LSD. However, there could be another mechanism at play that we don't know about.